期刊文献+
共找到83篇文章
< 1 2 5 >
每页显示 20 50 100
Pharmacokinetics of nifedipine sustained-release tablets in healthy Chinese volunteers 被引量:3
1
作者 武静 王本杰 +2 位作者 魏春敏 卜凡龙 郭瑞臣 《Journal of Chinese Pharmaceutical Sciences》 CAS 2007年第3期192-196,共5页
Aim To establish a LC-MS method for determining the concentration of nifedipine in human plasma and to evaluate the pharmacokinetic characteristics of nifedipine sustained-release tablets. Methods A XB-C18 (5 μm, 4.... Aim To establish a LC-MS method for determining the concentration of nifedipine in human plasma and to evaluate the pharmacokinetic characteristics of nifedipine sustained-release tablets. Methods A XB-C18 (5 μm, 4.6 mm ×150 mm) column and a mobile phase of methanol: 0.01 mol·L^-1ammonium acetate (60:40, V/V) were used to separate nifedipine, the detections was accuracy under atmosperic pressure electronic spray ionization (AP-ESI) mode and ion mass spectrum (m/z) of 314.9 [M+H]^+ for nifedipine, and 320.8 [M+H]^+ for lorazepam (Internal Standard, IS). Results The linear range of nifedipine was 0.3 - 80 ng·mL^-1 ( r = 0.9997), and the limit of quantitation (LOQ) was 0.3 ng·mL^-1. The nifedipine pharmacokinetic parameters after a single dose of 20 mg nifedipine sustained-release tablets test (T) or reference (R) were as the followings, t1/2 (6.73 ± 2.00) h and (7.04 ± 2.18) h, Tmax (4.28 ± 0.70) h and (4.48 ± 0.70) h, Cmax(39.66 ± 10.58) ng·mL^-1 and (40.19 ± 10.97) ng·mL^-1, AUC0-36 (391.63 ± 108.55) ng·mL^-1·h and (387.57 ± 121.51) ng·mL^-1·h, and AUC0-∞ (408.28 ± 121.16) ng·mL^-1·h and (406.15 ± 133.13) ng·mL^-1·h. The relative bioavailability of nifedipine sustained-release tablets (test) was (103.02 ± 13.93) %. Conclusion LC-MS method for the determination of concentrations of nifedipine in human plasma was sensitive and accurate, and could be used in nifedipine bioavailability and pharmacokinetic studies. 展开更多
关键词 Nifedipine sustained-release tablets LC-MS PHARMACOKINETICS BIOEQUIVALENCE
暂未订购
Qualitative and quantitative analysis of HPLC fingerprint of Wuji gastric floating sustained-release tablets 被引量:1
2
作者 陈中芬 刘文 +2 位作者 陈大业 施晓伟 王群 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2015年第5期310-317,共8页
A qualitative and quantitative test method of fingerprint of Wuji gastric floating sustained-release tablets was established. High performance liquid chromatography (HPLC) was adopted, using Agilent ZORBAX SB-C18 co... A qualitative and quantitative test method of fingerprint of Wuji gastric floating sustained-release tablets was established. High performance liquid chromatography (HPLC) was adopted, using Agilent ZORBAX SB-C18 column (250 mm×4.6 mm, 5 μm) as the chromatographic column, and acetonitrile-0.05 mol/L potassium dihydrogen phosphate solution as the mobile phase in a gradient elution with the flow rate of 1.0 mL/min. Sample solution (10 μL) was injected and was tested at the wavelength of 225 nm for 75 min at the column temperature of 30 ℃, Fingerprint similarity software (2004A version) was used to conduct data analysis. A total of 11 batches of Wuji gastric floating sustained-release tablets were tested and analyzed with HPLC fingerprint. Seventeen common peaks were found and the similarity of the 11 batches of agents was greater than 0.9, indicating that the production process of the agent is stable and feasible. The method is operable and could effectively control the quality of Wuji gastric floating sustained-release tablets. 展开更多
关键词 FINGERPRINT HPLC Wuji gastric floating sustained-release tablets
原文传递
Preparation and <i>in Vitro</i>Drug Release Evaluation of Once-Daily Metformin Hydrochloride Sustained-Release Tablets 被引量:1
3
作者 Ling Zhao Yumeng Wei +4 位作者 Yong Mei Li Yang Yuan You Xufeng Yang Yanhong Jiang 《Pharmacology & Pharmacy》 2012年第4期468-473,共6页
The objective of this study was to develop once-daily metformin hydrochloride sustained-release tablets (MHSRT) and evaluate their in vitro release behavior. MHSRT were prepared by the film coating method. The in vitr... The objective of this study was to develop once-daily metformin hydrochloride sustained-release tablets (MHSRT) and evaluate their in vitro release behavior. MHSRT were prepared by the film coating method. The in vitro drug release rate of MHSRT and the commercial tablets Fortamet? made in the United States of America in water was fitted with zero order kinetic equation, and Ritger-Peppas kinetic equation in 0.1 M HCl and pH 6.8-phosphate buffer, respectively. The similarity factor f2 values of MHSRT in three different dissolution medium were 82, 80 and 74, respectively in comparison with imported Fortamet?, which were all greater than 50. The results of storage-stability showed that MHSRT were stable for at least 6 months under stress condition (40℃ ± 2℃, RH 75% ± 5%). Therefore, in this study, MHSRT were successfully prepared using optimized formulation technologies that meet mass produce. The in vitro release behavior of MHSRT was almost similar to that of imported Fortamet?. 展开更多
关键词 sustained-release tablets METFORMIN HYDROCHLORIDE In Vitro Release Rate Similarity Factor Kinetic Model
暂未订购
Preparation and evaluation of sustained-release azithromycin tablets in vitro and in vivo
4
作者 Le Sun Weixiang Zhang +1 位作者 Xiaohong Liu Jin Sun 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2014年第3期155-161,共7页
The objective of this study was to prepare azithromycin(AZI)sustained-release products in order to allow for a high dose to be administered,reduce gastrointestinal side-effects and increase the compliance of patients.... The objective of this study was to prepare azithromycin(AZI)sustained-release products in order to allow for a high dose to be administered,reduce gastrointestinal side-effects and increase the compliance of patients.AZI sustained-release tablets with different release performance(F-I:T_(100%)=3 h and F-II:T_(100%)=8 h in pH 6.0 phosphate buffer)were successfully prepared by wet granulation.The in vitro release rate and drug release mechanism were studied.The release rate of F-Iwas affected by dissolutionmedia with different pH,but not for F-II.HixsoneCrowellmodel was the best regression fitting model for F-I and F-II.Additionally,F-I and F-II both belonged to non-Fick diffusion.Oral pharmacokinetics of the two tablets and one AZI dispersible tablet as reference were studied in six healthy beagle dogs after oral administration.Compared with the reference,the C_(max) of F-I and F-II were decreased,and the T_(max) were prolonged,in that case which meet the requirement of sustained-release tablets.The relative bioavailability of F-I and F-II were 79.12%and 64.09%.T-test ofAUC_(0-144),and AUC_(0-∞) for F-I and F-II indicated there was no significant difference between F-I and F-II.These mean that the extended release rate did not induce different pharmacokinetics in vivo. 展开更多
关键词 AZITHROMYCIN sustained-release tablet PHARMACOKINETICS UPLC-MS-MS
在线阅读 下载PDF
Structure based release kinetics analysis of doxazosin mesylate sustained-release tablets using micro-computed tomography
5
作者 Qian Liu Mengqing Zan +8 位作者 Hanhan Huang Hai Su Wenjing Zhang Lingyun Ma Guangchao Zhang Zunjian Zhang Jiwen Zhang Jianzhao Niu Mingdi Xu 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2024年第6期154-162,共9页
The structures of solid dosage forms determine their release behaviors and are critical attributes for the design and evaluation of the solid dosage forms.Here,the 3D structures of doxazosin mesylate sustained-release... The structures of solid dosage forms determine their release behaviors and are critical attributes for the design and evaluation of the solid dosage forms.Here,the 3D structures of doxazosin mesylate sustained-release tablets were parallelly assessed by micro-computed tomography(micro-CT).There were no significant differences observed in the release profiles between the RLD and the generic formulation in the conventional dissolution,but the generic preparation released slightly faster in media with ethanol during an alcohol-induced dose-dumping test.With their 3D structures obtained via micro-CT determination,the unique release behaviors of both RLD and the generic were investigated to reveal the effects of internal fine structure on the release kinetics.The structural parameters for both preparations were similar in conventional dissolution test,while the dissolutions in ethanol media showed some distinctions between RLD and generic preparations due to their static and dynamic structures.Furthermore,the findings revealed that the presence of ethanol accelerated dissolution and induced changes in internal structure of both RLD and generic preparations.Moreover,structure parameters like volume and area of outer contour,remaining solid volume and cavity volumewere not equivalent between the two formulations in 40%ethanol.In conclusion,the structure data obtained from this study provided valuable insights into the diverse release behaviors observed in various modified-release formulations in drug development and quality control. 展开更多
关键词 Doxazosin mesylate sustained-release tablets Osmotic pump tablets Micro-computed tomography Three-dimensional structures ETHANOL
暂未订购
Simultaneous Analysis of Indapamide and Related Impurities in Sustained-Release Tablets by a Single-Run HPLC-PDA Method
6
作者 YAO Wu ZHOU Shiwen CHENG Qiongru 《Wuhan University Journal of Natural Sciences》 CAS CSCD 2023年第4期333-340,共8页
The contents of indapamide and related impurities in generic indapamide sustained-release tablets were simultaneously detected by a single-run high performance liquid chromatography equipped with photodiode array dete... The contents of indapamide and related impurities in generic indapamide sustained-release tablets were simultaneously detected by a single-run high performance liquid chromatography equipped with photodiode array detector(HPLC-PDA)method for the quality control in this paper.The results showed the method had a good selectivity and was validated through linearity,limits of detection and quantification,recovery,and precision.The linear ranges of indapamide,2-methyl-1-nitroso-2,3-dihydro-1H-indole(impurity A,ImA),4-chloro-N-(2-methyl-1H-indol-1-yl)-3-sulphamoyl-benzamide(impurity B,ImB)and 4-chloro-3-sulfamoylbenzoic acid(impurity 1,Im1)were 0.028-1.80μg/mL(R=0.99995),0.060-1.20μg/mL(R=0.9996),0.0324-1.20μg/mL(R=0.99985)and 0.060-1.20μg/mL(R=0.9997)with detection limits of 0.0093,0.012,0.012 and 0.006μg/mL,respectively.ImA and Im1 were not detectable in the generic drug.The content of indapamide was 96.7%of the labeled amount with a relative standard deviation(RSD)of 1.30%,and the percentage of ImB relative to the labeled amounts of indapamide was 0.106%with an RSD of 1.82%.The content of other unspecified impurities all met the reference quality standards.The results provided references for the quality control and the quality standard study of generic indapamide sustained-release tablets. 展开更多
关键词 INDAPAMIDE related impurity sustained-release tablets high performance liquid chromatography equipped with photodiode array detector(HPLC-PDA)
原文传递
Clinical observation of Baitou Weng Decoction combined with mesalazine sustained-release tablets in treating heat-toxic and smoldering ulcerative colitis
7
作者 Qian-Zhang Ma Yun Li Yuan-Quan Ding 《Journal of Hainan Medical University》 2019年第12期37-42,共6页
Objective:To observe the clinical efficacy of Baitou Weng Decoction combined with mesalazine sustained-release tablets in the treatment of ulcerative colitis with febrile heat and its effect on immune function and ser... Objective:To observe the clinical efficacy of Baitou Weng Decoction combined with mesalazine sustained-release tablets in the treatment of ulcerative colitis with febrile heat and its effect on immune function and serum inflammatory factors.Methods: A total of 84 patients with ulcerative colitis were randomly divided into control group and treatment group, with 42 cases in each group. The control group was given mesalazine sustained-release tablets orally, while the treatment group was given Baitou Weng Decoction and mesalazine sustained-release tablets orally. The treatment period was 30 days and the patients were followed up for 3 months. After treatment, the clinical efficacy, quality of life, immune function and serum inflammatory factors of the two groups were observed.Results: The effective rate of treatment group (90.47%) was higher than that of control group (73.81%) (P<0.05);compared with before treatment, the scores of inflammatory bowel disease quality of life questionnaire scale in both groups were significantly improved (P<0.05), and the difference between the two groups was significant (P<0.05);after treatment, the plasma CD4+/CD8+ ratio and NK+ levels in both groups were significantly higher than those before treatment (P<0.05), and the treatment group was changed. The serum levels of tumor necrosis factor-α, interleukin-17 and interleukin-23 were significantly decreased in both groups after treatment (P<0.05), and the improvement was more significant in the treatment group (P<0.05). No significant adverse reactions were observed in the treatment group.Conclusions: Modified Baitou Weng Decoction combined with mesalazine in the treatment of heat-toxic and incandescent ulcerative colitis can significantly improve the clinical efficacy, improve the quality of life of patients, effectively regulate the expression level of serum inflammatory factors in ulcerative colitis patients, promote the recovery of patients' immune function, and have high drug safety. 展开更多
关键词 Baitou WENG DECOCTION MESALAZINE sustained-release tablets Hot toxicity ULCERATIVE colitis Immune function Serum inflammatory factor
暂未订购
Clinical observation on treatment of cancer pain with TCM oriented drugs combined with oxycodone sustained-release tablets and nimesulide sustained-release tablets
8
作者 Feng-Jiao He Ke-Xiong Li +2 位作者 Pu-Hua Zeng Hai-Yan Yi Xiao-Lan Jian 《TMR Cancer》 2018年第4期118-123,共6页
Objective: To study the effect of the transdermal preparation of traditional Chinese medicine in treating cancer pain. Methods: From October 2016 to January 2018, 126 patients with cancer pain were enrolled and divi... Objective: To study the effect of the transdermal preparation of traditional Chinese medicine in treating cancer pain. Methods: From October 2016 to January 2018, 126 patients with cancer pain were enrolled and divided into 4 groups, 39 patients in group A (directed TCM permeation), 26 patients in group B (oxycodone sustained-release tablets), 32 patients in group C (Chinese medicine directed drug penetration + oxycodone sustained-release tablets), and 29 patients group D (Chinese medicine directed drug penetration + oxycodone sustained-release tablets + nimesulide sustained release tablets), according to KPS scores. Results: Transdermal preparations of traditional Chinese medicine can significantly alleviate cancer pain. For the treatment of moderate to severe cancer pain, the Chinese medicine transdermal preparation can reduce the dosage of oxycodone sustained-release tablets. At the same time, the patient's KPS and NRS scores were significantly reduced. Moreover, the transdermal preparation of traditional Chinese medicine has a better therapeutic effect on visceral pain. Conclusion: The traditional Chinese medicine tra_nsdermal preparation combined with western medicine for the treatment of cancer pain may be a new method for the treatment of cancer pain. 展开更多
关键词 Chinese medicine directed drug Oxycodone sustained-release tablets Cancer pain Clinical efficacy
暂未订购
Clinical Effect of Nifedipine Sustained-release Tablets Combined with Enalapril in the Treatment of Elderly Patients with Coronary Heart Disease and Hypertension
9
作者 QU Zengqiang 《外文科技期刊数据库(文摘版)医药卫生》 2020年第2期092-094,共5页
Objective: To explore the therapeutic effect of nifedipine sustained-release tablets combined with enalapril in the treatment of elderly patients whose age above 60 years old with coronary heart disease and hypertensi... Objective: To explore the therapeutic effect of nifedipine sustained-release tablets combined with enalapril in the treatment of elderly patients whose age above 60 years old with coronary heart disease and hypertension. Methods: 260 elderly patients whose age above 60 years old with coronary heart disease and hypertension were selected and analyzed. The research time span was from August 2019 to April 2020. The patients were randomly divided into control group and observation group with 130 cases in each group. There was no significant difference in general data after statistical analysis. The treatment intervention program formulated by the control group was nifedipine sustained-release tablets, while the treatment intervention program formulated by the observation group was combined with enalapril on the basis of control group. The clinical value of nifedipine sustained-release tablets combined with enalapril was compared in the evaluation of condition control and safety of the two treatment regimens. Results: after the intervention of the two treatment schemes, the total effective rate of disease control treatment evaluation of elderly patients with coronary heart disease and hypertension was higher than that of the control group, and there were significant differences between groups, and statistical significance was indicated after analysis and calculation, (P < 0.05). There were no serious adverse reactions in the two groups during the treatment, there was no significant difference in the data between the groups, and there was no statistical significance after calculation and analysis, (P > 0.05). Conclusion: nifedipine sustained-release tablets combined with enalapril in the treatment of elderly patients with coronary heart disease and hypertension can achieve better clinical efficacy than use nifedipine sustained-release tablets alone, and will not increase the probability of adverse reactions, can improve the quality of life of patients, has the value of popularization and application. 展开更多
关键词 coronary heart disease HYPERTENSION elderly patients nifedipine sustained-release tablets enalap
暂未订购
Pharmacokinetic Study on Lovastatin Sustained-release Tablet and Sustained-release Capsule in Begal Dogs
10
作者 付琳 代宗顺 +1 位作者 侯淑贤 万元胜 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2004年第2期116-119,共4页
This study pharmacokinetically examined the lovastatin sustained-release tablet and sustained-release capsule in Beagle dogs. An reversed-phase HPLC method was established for the determination of lovastatin in Beagl... This study pharmacokinetically examined the lovastatin sustained-release tablet and sustained-release capsule in Beagle dogs. An reversed-phase HPLC method was established for the determination of lovastatin in Beagle dog plasma. Pharmacokinetic findings were compared among three preparation(lovastatin sustained-release tablet,T p; sustained-release capsule,T J and conventional capsule). Our results showed that the pharmacokinetic parameters in 6 dogs after single-dose oral administration of three perparations were calculated. T max, C max and MRT revealed significant difference (P<0.05). Relative bioavailability was 111.5±16.9 % (T P) and 110.4%±9.6 % (T J). The pharmacokinetic parameters in the 6 dogs after multiple-dose oral administration of three perparations, T max, C max MRT and DF had significant difference (P<0.05); C av , C min and AUC 0-24 h displayed no significant difference (P>0.05). It is concluded that the lovastatin sustained-release tablet and sustained-release capsule are able to maintain a sustained-release for 24 h. 展开更多
关键词 LOVASTATIN sustained-release tablets sustained-release capsules PHARMACOKINETIC SINGLE-DOSE MULTIPLE-DOSE
暂未订购
Observation on Effect of Methimazole Combined with Propranolol Sustained Release Tablets in the Treatment of Hyperthyroidism and Analysis of the Influence of FT4 and FT3 Levels
11
作者 MAJianhui 《外文科技期刊数据库(文摘版)医药卫生》 2022年第10期096-100,共5页
Objective: To evaluate the efficacy of methimazole combined with propranolol sustained-release tablets in the treatment of hyperthyroidism and its influence on FT4 and FT3 levels. Methods: Eighty-six hyperthyroidism p... Objective: To evaluate the efficacy of methimazole combined with propranolol sustained-release tablets in the treatment of hyperthyroidism and its influence on FT4 and FT3 levels. Methods: Eighty-six hyperthyroidism patients who are fully aware of the research content and voluntarily participate in the research were selected as the research samples. The first patient and the last patient were treated in our hospital in January 2021 and December 2021, respectively, and they were equally divided into two groups. There were two groups, one group was named as the control group, the other group was named as the observation group, and the treatment drug was methimazole combined with propranolol sustained-release tablets. Results: The indexes selected in the study were thyroid index, serum index, therapeutic effect and adverse reactions. The data obtained were analyzed and compared between groups, and the observation group was better than the control group (P 0.05). Conclusion: When treating patients with hyperthyroidism clinically, the scheme of methimazole combined with propranolol sustained-release tablets can not only effectively improve the thyroid index of patients, but also relieve their related symptoms, which has high clinical application value. 展开更多
关键词 HYPERTHYROIDISM METHIMAZOLE Propranolol sustained-release tablets FT4 and FT3 levels
暂未订购
盐酸哌甲酯缓释剂对注意缺陷多动障碍儿童骨密度的影响
12
作者 董慧 董孝云 +2 位作者 胡博 王少雯 张贻霞 《临床心身疾病杂志》 2025年第6期11-14,共4页
目的了解盐酸哌甲酯缓释剂对注意缺陷多动障碍儿童骨密度的影响。方法选取的168例注意缺陷多动障碍患儿(研究组)均应用盐酸哌甲酯缓释剂治疗,治疗28周。于治疗前、治疗12周和治疗28周测定研究组患儿的骨密度,入组时测定168名健康儿童(... 目的了解盐酸哌甲酯缓释剂对注意缺陷多动障碍儿童骨密度的影响。方法选取的168例注意缺陷多动障碍患儿(研究组)均应用盐酸哌甲酯缓释剂治疗,治疗28周。于治疗前、治疗12周和治疗28周测定研究组患儿的骨密度,入组时测定168名健康儿童(对照组)的骨密度。比较两组受试者的骨密度,并分析治疗前后研究组不同年龄段受试者的骨密度。结果治疗前,研究组受试者骨密度与对照组比较,差异无统计学意义(P>0.05);治疗12周、28周,研究组受试者骨密度较治疗前降低,且低于对照组(P<0.01)。治疗后,6~8岁、9~11岁、12~14岁3个年龄段研究组受试者骨密度均呈下降趋势(P<0.01)。结论在注意缺陷多动障碍患儿中,盐酸哌甲酯缓释剂的使用可能会导致骨密度的降低,临床应定期监测骨密度,探讨优化骨骼健康的方法。 展开更多
关键词 注意缺陷多动障碍 盐酸哌甲酯缓释剂 骨密度 儿童
暂未订购
哌甲酯缓释片联合认知行为干预对多动症患儿注意力、冲动行为及智力的影响
13
作者 张光林 傅敏 张爱娟 《天津药学》 2025年第9期1065-1069,共5页
目的探讨哌甲酯缓释片联合认知行为干预对多动症(ADHD)患儿注意力、冲动行为及智力的影响。方法选取2023年1月至2024年12月在三明市第二医院就诊的76例ADHD患儿,按随机数字表法分为两组,各38例。对照组予以哌甲酯缓释片治疗,观察组在对... 目的探讨哌甲酯缓释片联合认知行为干预对多动症(ADHD)患儿注意力、冲动行为及智力的影响。方法选取2023年1月至2024年12月在三明市第二医院就诊的76例ADHD患儿,按随机数字表法分为两组,各38例。对照组予以哌甲酯缓释片治疗,观察组在对照组基础上实施认知行为干预治疗。治疗3个月后,对比两组注意力、冲动行为和智力。结果治疗后,观察组数字划消评分为(65.57±2.92)分,连接数字评分为(60.15±2.98)分,符号记入评分为(64.31±3.05)分,均高于对照组的(60.86±2.83)分、(54.49±2.84)分、(53.64±2.71)分,有统计学差异(t=7.140、8.476、16.121,P均<0.001);观察组Conners儿童行为问卷(CRS)评分为(33.18±3.04)分,低于对照组的(41.43±3.46)分,有统计学差异(t=11.042,P<0.001);观察组中国韦氏学龄儿童智力量表(C-WISC)中全量表智商评分为(111.85±3.88)分,言语量表智商评分为(109.96±3.35)分,操作量表智商评分为(108.61±3.24)分,均高于对照组的(103.12±3.73)分、(99.14±3.15)分、(97.16±3.18)分,有统计学差异(t=9.999、14.505、15.547,P均<0.001)。结论哌甲酯缓释片联合认知行为干预应用在ADHD患儿中,可显著提高其注意力及智力,减少冲动行为。 展开更多
关键词 多动症 哌甲酯缓释片 认知行为干预 注意力 冲动行为 智力
暂未订购
多动宁联合盐酸哌甲酯治疗注意力缺陷多动障碍患儿的疗效及安全性 被引量:1
14
作者 吴小丽 朱晶波 陈海燕 《中国药物应用与监测》 2025年第2期319-323,共5页
目的探讨多动宁胶囊联合盐酸哌甲酯片治疗注意力缺陷多动障碍患儿的临床效果及安全性。方法选取2022年1月至2024年10月海安市人民医院收治的116例注意力缺陷多动障碍患儿,采用随机数字表法分为对照组和观察组,每组58例。研究过程中对照... 目的探讨多动宁胶囊联合盐酸哌甲酯片治疗注意力缺陷多动障碍患儿的临床效果及安全性。方法选取2022年1月至2024年10月海安市人民医院收治的116例注意力缺陷多动障碍患儿,采用随机数字表法分为对照组和观察组,每组58例。研究过程中对照组脱落2例,最终纳入56例;观察组脱落3例,最终纳入55例。对照组口服盐酸哌甲酯片治疗,观察组在对照组的基础上加用多动宁胶囊治疗,疗程均为1个月。观察指标包括临床治疗效果、注意力涣散好转时间、活动过度好转时间、情绪不稳定好转时间、六项中医症候积分、注意缺陷多动障碍评定量表(SNAP-Ⅳ)评分、康纳氏父母症状问卷(PSQ)评分、血清25-羟维生素D3水平及药品不良反应情况。结果观察组治疗总有效率为96.36%(53/55),高于对照组的83.93%(47/56)(χ^(2)=4.806,P<0.05)。观察组注意力涣散好转时间(11.63±1.76)d、活动过度好转时间(10.45±0.99)d、情绪不稳定好转时间(9.56±1.34)d均短于对照组[分别为(15.23±2.12)d、(14.65±1.56)d、(13.65±2.06)d],t值分别为9.741、16.967、12.375,均P<0.001。治疗后,观察组六项中医症候积分、SNAP-Ⅳ评分、PSQ评分均低于对照组(均P<0.05)。治疗后,观察组血清25-羟维生素D3水平[(14.67±1.99)μg·L^(-1)]高于对照组[(11.95±2.03)μg·L^(-1)],t=8.929,P<0.001。两组不良反应发生率分别为3.64%(2/55)和3.57%(2/56),差异无统计学意义(P>0.05)。结论多动宁胶囊联合盐酸哌甲酯片治疗注意力缺陷多动障碍效果显著,能有效改善患儿症状,缩短症状缓解时间,且安全性良好。 展开更多
关键词 注意力缺陷多动障碍 多动宁胶囊 盐酸哌甲酯片 治疗效果 药品不良反应 中医症候积分 SNAP-Ⅳ评分 PSQ评分
暂未订购
脑肠轴理论指导下宁心安神汤对注意力缺陷多动障碍干预效果及对患儿肠道菌群的影响分析
15
作者 袁帅 刘婧 +2 位作者 鲍远军 黄肇华 许佳 《中华中医药学刊》 北大核心 2025年第8期22-25,共4页
目的分析脑肠轴理论指导下宁心安神汤治疗注意力缺陷多动障碍(Attention-deficit hyperactivity disorder,ADHD)患儿对肠道菌群的影响。方法纳入102例注意力缺陷多动障碍患儿为研究对象,随机数字表法分为两组,对照组51例采用盐酸哌甲酯... 目的分析脑肠轴理论指导下宁心安神汤治疗注意力缺陷多动障碍(Attention-deficit hyperactivity disorder,ADHD)患儿对肠道菌群的影响。方法纳入102例注意力缺陷多动障碍患儿为研究对象,随机数字表法分为两组,对照组51例采用盐酸哌甲酯片治疗,观察组51例在对照组基础上联合宁心安神汤治疗,对比两组疗效差异、症状评分、注意力缺陷多动障碍量表(Swanson,nolan and pelham-Ⅳrating scales,SNAP-Ⅳ)、数字划消失实验(NCT)失误率、儿童行为量表(Child behavior checklist,CBCL)以及肠道菌群指标变化情况等。结果观察组治疗总有效率为96.08%(49/51),远高于对照组的78.43%(40/51)(P<0.05);治疗后观察组多动不宁、神思涣散、多言多语、性急易怒评分均低于对照组,且治疗后观察组SNAP-Ⅳ评分、NCT失误率低于对照组,CBCL评分高于对照组(P<0.05);治疗后观察组双歧杆菌、乳酸菌、粪杆菌水平高于对照组,肠球菌低于对照组(P<0.05)。结论脑肠轴理论指导下宁心安神汤治疗注意力缺陷多动障碍效果明确,可调节其肠道菌群平衡,增加双歧杆菌和乳杆菌含量,能有效改善患儿症状,提高注意能力及认知功能,具有较高应用价值。 展开更多
关键词 脑肠轴理论 宁心安神汤 注意力缺陷多动障碍 肠道菌群 盐酸哌甲酯片
原文传递
盐酸哌甲酯缓释片对儿童注意缺陷多动障碍影响观察
16
作者 郑碧青 王晶 赵梦菲 《航空航天医学杂志》 2025年第6期641-643,共3页
目的分析盐酸哌甲酯缓释片对儿童注意缺陷多动障碍的影响。方法总计纳入66例注意缺陷多动障碍儿童(2022年03月~2024年02月收治)以随机数字表法进行分组,将入组儿童分为对照组与研究组,给予对照组儿童(33例)感统训练、脑电生物反馈治疗,... 目的分析盐酸哌甲酯缓释片对儿童注意缺陷多动障碍的影响。方法总计纳入66例注意缺陷多动障碍儿童(2022年03月~2024年02月收治)以随机数字表法进行分组,将入组儿童分为对照组与研究组,给予对照组儿童(33例)感统训练、脑电生物反馈治疗,研究组儿童(33例)在对照组治疗基础上结合盐酸哌甲酯缓释片治疗,各组儿童数据比较:疗效、治疗前后中文版评定量表父母版(SwansonNolan,and Pelham-Ⅳrating scales,SNAP-Ⅳ)评分变化、不良反应。结果研究组儿童治疗总有效率比对照组高,P<0.05;治疗前各组儿童SNAP-Ⅳ评分比较,P>0.05,治疗后各组儿童SNAP-Ⅳ评分均下降,研究组儿童治疗后SNAP-Ⅳ评分比对照组更低,P<0.05;研究组与对照组儿童不良反应率均较低,患儿可耐受,P>0.05。结论盐酸哌甲酯缓释片对儿童注意缺陷多动障碍具有积极影响,药物效果佳,患儿症状改善,不良反应少,药效安全、可靠。 展开更多
关键词 儿童注意缺陷多动障碍 盐酸哌甲酯缓释片 疗效 不良反应
暂未订购
盐酸哌甲酯缓释片辅助治疗对注意缺陷多动障碍患儿SNAP-Ⅳ评分及PRL、S100β水平的影响
17
作者 亓雪梅 《中国医药科学》 2025年第10期75-79,共5页
目的研究注意缺陷多动障碍患儿应用盐酸哌甲酯缓释片辅助治疗对患儿症状表现及相关血清蛋白、神经递质的影响。方法选取2022年4月至2024年3月泰安市妇幼保健院儿童心理卫生门诊进行治疗的注意缺陷多动障碍患儿126例为研究对象,以抽签法... 目的研究注意缺陷多动障碍患儿应用盐酸哌甲酯缓释片辅助治疗对患儿症状表现及相关血清蛋白、神经递质的影响。方法选取2022年4月至2024年3月泰安市妇幼保健院儿童心理卫生门诊进行治疗的注意缺陷多动障碍患儿126例为研究对象,以抽签法随机分为两组,每组各63例,对照组实施注意缺陷多动障碍执行功能训练,观察组在执行功能训练基础上服用盐酸哌甲酯缓释片辅助治疗。治疗前后观察两组患儿症状改善情况、相关血清蛋白及神经递质水平、总体智力变化。结果治疗前两组患儿注意缺陷多动障碍评定量表(SNAP-IV)量表评分比较,差异无统计学意义(P>0.05),治疗后两组SNAP-IV各项维度评分与治疗前比较均明显下降,差异有统计学意义(P<0.05),且观察组SNAP-Ⅳ评分低于对照组,差异有统计学意义(P<0.05)。治疗后第1、2个月观察组催乳素(PRL)、中枢神经特异性蛋白β(S100β)、神经递质水平5-羟色胺(5-HT)、去甲肾上腺素(NE)的水平均高于对照组,差异有统计学意义(P<0.05);观察组中等及以上智力患儿占比高于对照组,差异有统计学意义(P<0.05)。结论注意缺陷多动障碍患儿的临床治疗中加入盐酸哌甲酯缓释片进行辅助治疗可有效提高临床疗效,对患儿注意缺陷多动障碍的症状表现具有良好的改善效果,并能提高相关血清蛋白指标与神经递质表达水平,使患儿智力水平得到提高。 展开更多
关键词 盐酸哌甲酯缓释片 注意缺陷多动障碍 智力水平 中枢神经特异性蛋白β 5-羟色胺
暂未订购
盐酸哌甲酯控释片治疗儿童注意缺陷多动障碍疗效 被引量:22
18
作者 陈敏 华丽 +3 位作者 刘琳 徐璐 郝燕 侯凌 《医药导报》 CAS 2015年第10期1318-1321,共4页
目的:研究盐酸哌甲酯控释片治疗儿童注意缺陷多动障碍( ADHD)的疗效。方法将72例ADHD患儿随机分成治疗组40例和对照组32例。治疗组给予盐酸哌甲酯控释片,初始剂量为每天0.5 mg·kg-1,根据患儿病情和耐受程度逐步增加至每天0.8... 目的:研究盐酸哌甲酯控释片治疗儿童注意缺陷多动障碍( ADHD)的疗效。方法将72例ADHD患儿随机分成治疗组40例和对照组32例。治疗组给予盐酸哌甲酯控释片,初始剂量为每天0.5 mg·kg-1,根据患儿病情和耐受程度逐步增加至每天0.8~1.0 mg·kg-1,持续治疗3个月。对照组给予盐酸托莫西汀胶囊,初始剂量为每天0.5 mg·kg-1,根据患儿病情和耐受程度逐步增加至每天1.2~1.4 mg·kg-1,均于每日早餐后单次服药,疗程3个月。治疗前和治疗第12周进行韦氏智力测验、视听整合连续测试(IVA-CPT)、注意缺陷多动症状评估量表(SNAP-Ⅳ)和不良反应症状量表(TESS)评定。结果两组治疗后儿童注意缺陷及多动症状明显改善,韦氏智测评分明显增高(P〈0.05),SNAP-IV评分明显降低(P〈0.05),IVA-CPT评分明显提高(P〈0.05)。治疗组多动分数变化大于对照组(P〈0.05);治疗组听觉注意、视觉注意变化得分大于对照组( P〈0.05);治疗组食欲下降10例,对照组14例。治疗组嗜睡1例,对照组5例( P〈0.05)。治疗组入睡困难6例,对照组1例( P〈0.05)。治疗组1例在治疗第4个月出现一过性抽动症状。结论盐酸哌甲酯控释片和盐酸托莫西汀均能快速有效改善儿童注意缺陷和多动症状,同时提高患儿的学习功能,而盐酸哌甲酯控释片改善速度更快。 展开更多
关键词 哌甲酯控释片 盐酸 托莫西汀 盐酸 注意缺陷多动障碍
暂未订购
盐酸哌甲酯控释片联合小儿智力糖浆治疗儿童多动症的临床效果及安全性 被引量:30
19
作者 向魏坪 姚玲 《中国妇幼保健》 CAS 2017年第12期2637-2640,共4页
目的观察盐酸哌甲酯控释片联合小儿智力糖浆治疗儿童多动症(ADHD)临床疗效及药物不良反应,为ADHD治疗方案的选择提供参考依据。方法选择2010年1月-2016年10月天津市第五中心医院诊治的ADHD患儿108例作为研究对象,将其按照就诊顺序编号,... 目的观察盐酸哌甲酯控释片联合小儿智力糖浆治疗儿童多动症(ADHD)临床疗效及药物不良反应,为ADHD治疗方案的选择提供参考依据。方法选择2010年1月-2016年10月天津市第五中心医院诊治的ADHD患儿108例作为研究对象,将其按照就诊顺序编号,采用数字随机表法将患儿分为A、B、C 3组,每组36例,A组采用盐酸哌甲酯控释片治疗,B组采用小儿智力糖浆治疗,C组采用盐酸哌甲酯控释片联合小儿智力糖浆治疗,3组患儿均连续治疗3个疗程,比较3组患儿治疗前后的多动症评分变化及治疗后临床疗效,治疗过程中出现的药物不良反应。结果两组患儿性别、年龄、体质量、体质量指数、ADHD病程、ADHD病情严重程度分级、入组时ADHD行为量表评分比较,差异无统计学意义(P>0.05)。3组患儿完成3个治疗疗程后,多动症评分均较治疗前有明显降低(P<0.05),但C组患儿降低幅度明显高于A组和B组,B组降低幅度低于A组(P<0.05)。C组患儿临床总有效率明显高于A、B组患儿,A组患儿临床总有效率明显高于B组患儿(P<0.05)。A、C组患儿治疗过程中出现药物不良反应率高于B组患儿(P<0.05),A、C两组患儿药物不良反应比较差异无统计学意义(P>0.05)。结论盐酸甲酯控释片联合小儿智力糖浆治疗小儿多动症临床疗效较满意,但在临床治疗方案制定时应充分考虑患儿身体条件,充分考虑药物不良反应对患儿生长发育可能造成的影响,提高患儿治疗时的安全性。 展开更多
关键词 儿童多动症 盐酸哌甲酯控释片 小儿智力糖浆 临床疗效 药物不良反应
原文传递
盐酸哌甲酯缓释片联合脑电生物反馈加感统训练治疗儿童注意缺陷多动障碍的临床疗效研究 被引量:41
20
作者 徐玄玄 潘凯 +1 位作者 张怡妍 王亚哲 《实用医院临床杂志》 2022年第3期24-27,共4页
目的探讨盐酸哌甲酯缓释片联合脑电生物反馈加感统训练治疗儿童注意缺陷多动障碍(ADHD)的临床疗效及可行性。方法2018年12月至2020年12月三门峡中心医院收治的ADHD患儿128例,根据治疗方案不同分为对照组67例(脑电生物反馈加感统训练治疗... 目的探讨盐酸哌甲酯缓释片联合脑电生物反馈加感统训练治疗儿童注意缺陷多动障碍(ADHD)的临床疗效及可行性。方法2018年12月至2020年12月三门峡中心医院收治的ADHD患儿128例,根据治疗方案不同分为对照组67例(脑电生物反馈加感统训练治疗)、观察组61例(脑电生物反馈加感统训练+口服盐酸哌甲酯缓释片治疗)。6周为1个疗程,持续2个疗程。比较两组治疗前后SNAP-IV评定量表评分、智力情况、脑电波频率。结果治疗后两组SNAP-IV评定量表评分(注意力不足、过动/冲动、对立违抗、全量表)均明显下降,C-WISC量表评分(全量表智商、言语量表智商及操作量表智商)均明显升高,且观察组较对照组改变更明显,差异均有统计学意义(P<0.05)。治疗后两组β波、SMR波明显升高,θ波明显下降(P<0.05),且观察组β波、SMR波升高幅度大于对照组,θ波下降幅度大于对照组(P<0.05)。两组均无严重不良反应发生。结论脑电生物反馈加感统训练治疗联合盐酸哌甲酯缓释片治疗ADHD患儿能提高患儿行为能力、认知功能,改善脑电波频率,是一种安全、可行的方案。 展开更多
关键词 盐酸哌甲酯缓释片 脑电生物反馈 感统训练 注意缺陷多动障碍
暂未订购
上一页 1 2 5 下一页 到第
使用帮助 返回顶部